UBS Group
CTOR icon

UBS Group’s Citius Oncology CTOR Stock Holding History

UBS Group’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.1K Sell
13,982
-320,637
-96% -$251K ﹤0.01% 8783
2026
Q2 		$218K Buy
334,619
+297,779
+808% +$237K ﹤0.01% 6740
2026
Q1 		$22.8K Buy
36,840
+15,376
+72% +$15.4K ﹤0.01% 7836
2025
Q4 		$21.5K Buy
21,464
+21,409
+38,925% +$30.7K ﹤0.01% 7735
2025
Q3 		$112 Sell
55
-15,368
-100% -$33.3K ﹤0.01% 9902
2025
Q2 		$67.1K Sell
15,423
-34,322
-69% -$40.1K ﹤0.01% 7540
2025
Q1 		$46.3K Buy
49,745
+24,940
+101% +$26.7K ﹤0.01% 7651
2024
Q4 		$28.5K Buy
24,805
+23,173
+1,420% +$26K ﹤0.01% 7641
2024
Q3 		$2.27K Buy
+1,632
New +$11.6K ﹤0.01% 8471
2023
Q2 		– Sell
-1,504
Closed -$15.6K – 9791
2023
Q1 		$15.6K Buy
1,504
+1,104
+276% +$11.3K ﹤0.01% 7285
2022
Q4 		$4.06K Buy
+400
New +$4.06K ﹤0.01% 9395

Other funds holding CTOR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group's CTOR Position: Q3 2026 in Review

UBS Group reduced its Citius Oncology (CTOR) stake by 96% in Q3 2026, selling an estimated $251K and leaving 13,982 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #8783.

UBS Group first reported a position in CTOR in Q4 2022 and has held it in 11 quarters since. The position peaked at $218K in Q2 2026. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2026.

  • UBS Group held 13,982 shares of Citius Oncology worth $14.1K as of Q3 2026.
  • UBS Group sold 320,637 Citius Oncology shares in Q3 2026, an estimated $251K.
  • Citius Oncology made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8783 holding.
  • UBS Group first reported a position in Citius Oncology in Q4 2022 and has held it in 11 quarters since.
  • UBS Group's Citius Oncology position peaked at $218K in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.